Zevra Therapeutics
ZVRA
108 hedge funds and large institutions have $201M invested in Zevra Therapeutics in 2024 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 37 increasing their positions, 19 reducing their positions, and 12 closing their positions.
231% more call options, than puts
Call options by funds: $6.94M | Put options by funds: $2.1M
156% more capital invested
Capital invested by funds: $78.6M → $201M (+$122M)
125% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 12
95% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 19
16.69% more ownership
Funds ownership: 38.33% → 55.03% (+17%)
16% more funds holding
Funds holding: 93 → 108 (+15)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$19.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$15.7M |
| 3 |
JGC
J. Goldman & Co
New York
|
+$6.68M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.26M |
| 5 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$4.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$890K |
| 2 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
-$867K |
| 3 |
Renaissance Technologies
New York
|
-$553K |
| 4 |
SA
Sanctuary Advisors
Indianapolis,
Indiana
|
-$523K |
| 5 |
BGIM
Brandywine Global Investment Management
Philadelphia,
Pennsylvania
|
-$514K |
ZVRA Hedge Fund Activity: Q3 2024 in Review
108 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Zevra Therapeutics (ZVRA) for Q3 2024, worth a combined $201M — up 156% from $78.6M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new ZVRA positions and 12 closed out — a net gain of 15 holders — while 37 added to existing stakes and 19 trimmed.
The largest buyer was Woodline Partners, adding an estimated $19.7M. The largest seller was AIGH Capital Management, exiting entirely with an estimated $890K sold.
- 108 institutional investors held Zevra Therapeutics (ZVRA) as of Q3 2024, up from 93 in Q2 2024.
- Funds reported $201M of Zevra Therapeutics stock for Q3 2024, up 156% quarter-over-quarter.
- 27 funds opened new Zevra Therapeutics positions in Q3 2024 and 12 closed out, a net change of +15 holders.
- The largest Zevra Therapeutics buyer in Q3 2024 was Woodline Partners, an estimated $19.7M added.
- The largest Zevra Therapeutics seller in Q3 2024 was AIGH Capital Management, an estimated $890K sold.
Based on aggregated 13F filings for Q3 2024.